1,600 results on '"Halperin, Jonathan L"'
Search Results
102. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary
103. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
104. Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
105. Anticoagulant Selection in Relation to SAMe-TT$_{2}$R$_{2}$ Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry
106. Prevention of stroke in patients with atrial fibrillation: Anticoagulant and antiplatelet options
107. Stroke Prevention in the High-risk Atrial Fibrillation Patient: Medical Management
108. Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
109. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
110. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
111. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
112. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial
113. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
114. An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation
115. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
116. Early management of atrial fibrillation to prevent cardiovascular complications
117. Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation
118. Non-Vitamin K Antagonist Oral Anticoagulants: An Appeal for Consensus on Terminology
119. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
120. B-PO01-082 ARTIFICIAL INTELLIGENCE-ASSISTED QRS AMPLITUDE ANALYSIS OF THE PRESENTING ELECTROCARDIOGRAM PREDICTS MORTALITY IN COVID-19
121. Antithrombotic Therapy to Reduce Mortality in Patients With Atherosclerosis
122. Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
123. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
124. Oral anticoagulation
125. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials
126. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial
127. Prognostic Value of Electrocardiographic QRS Diminution in Patients With COVID-19
128. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial
129. Low-Dose Anticoagulation for Atrial Fibrillation
130. Raynaud's Phenomenon
131. Contributors
132. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
133. Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
134. Rationale and design of REVEAL AF: A prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients
135. Atrial Fibrillation and Flutter
136. Edoxaban versus Warfarin in Patients with Atrial Fibrillation
137. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
138. ACCF/AHA/SCAI 2013 Update of the Clinical Competence Statement on Coronary Artery Interventional Procedures: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Revise the 2007 Clinical Competence Statement on Cardiac Interventional Procedures)
139. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions
140. Oral anticoagulants in the management of venous thromboembolism
141. Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy: A Subgroup Analysis of a Randomized Trial
142. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
143. Active-control clinical trials to establish equivalence or noninferiority: Methodological and statistical concepts linked to quality
144. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
145. STROKE: Finding atrial fibrillation after cryptogenic stroke
146. Management of Atrial Fibrillation: Direct Factor IIa and Xa Inhibitors or “Warfarin Shotgun”?
147. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit
148. Subclinical Atrial Fibrillation and the Risk of Stroke
149. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (Updating the 2005 guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery
150. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.